Omnicare Inc

Omnicare — Q3 2011 Earnings Presentation

18 slides from Omnicare's earnings presentation, Oct 25, 2011

  1. Slide 1: Third Quarter 2011 Financial Results Supplemental Slides

    Third Quarter 2011 Financial Results Supplemental Slides

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for historical information discussed, the statements made today and listed within the following presentation slides are forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual

  3. Slide 3: Table of Contents

    Table of Contents Third Quarter 2011 Highlights………..………………………………………..4 Operating Metrics - Script Data………………………………………………. 5 Operating Metrics - Bed Data………………………………………………… 6 Adjusted Gross Profit………………...………………………………………...7 Adjusted Net Income……………………………………………………………8 Cash Flows…………………………………………………………

  4. Slide 4: Third Quarter 2011 Highlights

    Third Quarter 2011 Highlights • Gross profit increased 2.9% sequentially to $346.1M on 0.7% decrease in sales – Gross margin sequentially higher by 79 bps to 22.4%, reflecting higher generic dispensing rates • Cash flows from continuing operations of $167.1M increased 22.1% sequentially and 43.7% ov

  5. Slide 5: Operating Metrics - Script Data

    • Generic dispensing rate climbed 60 bps sequentially to 78.6% due primarily to additional generic drug introductions • Sequentially, scripts were down 0.8% reflecting a lower average number of beds served and weaker utilization (consistent with industry) • Scripts relatively even from 3Q10 (1) 3Q 2

  6. Slide 6: Operating Metrics - Bed Data

    Operating Metrics Bed Data • Organic bed loss includes: • 3,000 incremental bed losses due to compliance and receivables collections issues as compared with 2Q11 • 1,000 beds lost from business acquired in the past year • Organic net bed growth in 2 of 5 divisions • Beds added by acquisition: • 3Q11

  7. Slide 7: Adjusted Gross Profit

    Adjusted Gross Profit (1) (1) Each amount is reported independently. The sum of the individual amounts may not equal the sum of the separately presented amounts due to rounding. (2) Excludes special items. A reconciliation of non-GAAP information has been attached to our press release and is also av

  8. Slide 8: Adjusted Net Income

    Adjusted Net Income (1),(2) (1) All numbers shown exclude special items and discontinued operations. A reconciliation of non-GAAP information has been attached to our press release and is also available on our Web site under ‘Supplemental Financial Information’ from the ‘Investors’ page. (2) Each am

  9. Slide 9: Cash Flows

    Cash Flows (1) • Year-to-date cash flows from operating activities of continuing operations of $447.9M represents the largest cash flow generated in the Company’s history in any nine-month reporting period • 3Q11 cash flows benefitted from $22.7 million settlement of a receivable dispute with a larg

  10. Slide 10: Cash Deployment

    • Repurchased an additional 1.8 million shares ($50.1 million) during 3Q11 (in addition to 2.3 million shares repurchased through 2Q11 and 4.4 million repurchased in 2010) • $78.9 million of authorization remaining under current share repurchase program as of September 30, 2011. • 3Q11 dividend of $

  11. Slide 11: Capital Structure

    Capital Structure Goal is to spread out maturities to limit refinancing risk (1) Assumes convertible debentures due 2035 are put to the company in 2015 with related tax recapture included and debt amounts shown are exclusive of unamortized debt discount. 11

  12. Slide 12: 2011 Guidance

    2011 Guidance Previous Guidance (1) Current Guidance (2) • Revenues $6.0B to $6.1B $6.0B to $6.1B • Adjusted Diluted EPS (3) $2.05 to $2.15 $2.09 to $2.13 • Cash Flow from Operations (3) $400M to $450M $500M to $525M Increased cash flow guidance, narrowed EPS guidance and reaffirmed sales guidance (

  13. Slide 13: Longer-Term Targets

    Longer-Term Targets (1) Target Double digit three-year CAGR • Adjusted Diluted EPS for the year ending 2013 • Cash Flow from Operations $450 million annually • Capital Returned to Shareholders Approximately 25% per year (2) Focus on continued debt reduction, • Capital Structure management of maturit

  14. Slide 14: Appendix

    Appendix 14

  15. Slide 15: Working Capital Management

    Working Capital Management Five Quarter Trend 30 + 20 10 80 5 : 5 + 74 311 504 27.6 27.4 29.1 67.9 68 63.5 _ 61.4 62 59.9 58.2 56 3Q10 4Q10 1Q11 2Q11 3Q11 —@— Days of Inventory On Hand (DOH) — Days Sales Outstanding (DSO)

  16. Slide 16: Selected Branded Drug Patent Expirations

    Selected Branded Drug Patent Expirations (1),(2) 3Q 2011 4Q 2011 FY 2012 Arixtra Caduet Actos Entocort EC Combivir Detrol Felbatol Gabitril Diovan Keppra XR Lipitor Geodon Levaquin IV Primaxin Fazaclo Uroxatrol Requip XL Lexapro Symbyax Lidoderm Zyprexa Injectable Plavix Zyprexa Tabs Seroquel Zyprex

  17. Slide 17: Third Quarter 2011 Financial Results Supplemental Slides

    Third Quarter 2011 Financial Results Supplemental Slides

  18. Slide 18: Slide 18

Omnicare — Q3 2011 Earnings Presentation on 6ix